Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Japan’s Medical Big Data Market to Top 700 Billion Yen in 2035: Fuji Keizai
June 3, 2022
- Astellas, US-Based GO to Codevelop New Immuno-Oncology Antibodies
June 2, 2022
- Fujifilm Kicks Off US PIIa Study for Liposome Cancer Drug in Combo with Keytruda
June 2, 2022
- Kyowa Kirin, InveniAI Hit 1st Milestone under Drug Discovery Deal
June 2, 2022
- Japan’s 1st Tardive Dyskinesia Drug Hits Market, Otsuka’s Eczema Ointment Too
June 2, 2022
- Shashank Deshpande to Take Reins at Nippon Boehringer Ingelheim
June 2, 2022
- Takeda to Transfer Spikevax Authorization to Moderna in Japan, 3-Way Purchase Deal to End
June 1, 2022
- Psoriasis Med Bimzelx Anticipated to Treat 10,000 Patients: UCB Japan
May 31, 2022
- Kaken’s Spanish Partner Files Efinaconazole in Europe
May 31, 2022
- Takhzyro, Samsca Prodrug, EA Pharma’s UC Drug Now Available in Japan
May 31, 2022
- Japan Drug Majors Expand Global Oncology Sales in FY2021
May 30, 2022
- Tokyo Court Nixes Chugai’s Method-of-Use Patent Claim for Edirol
May 30, 2022
- Detailing Activities Log Two-Digit Growth MOM in All Promotion Channels in March: Intage
May 30, 2022
- Moderna Eyes Bivalent Booster Rollout This Fall via Emergency Approval Path in Japan: CMO
May 30, 2022
- Creditors Defer Debts for Nichi-Iko until Turnaround Plan Is Approved
May 27, 2022
- COVID-19 Booster Study Shows Efficacy: Daiichi Sankyo
May 27, 2022
- AstraZeneca Tops Foreign Pharma Ranking in 2021, Pfizer Sales Undisclosed: Jiho
May 27, 2022
- Top 4 Wholesalers Log 62% Rise in Operating Profit in FY2021 on Rebound in Doctor Visits
May 27, 2022
- Pharmira Looks to Offer One-Stop API/Intermediate CDMO Services, Expand with Continuous Manufacturing Tech
May 27, 2022
- Sandoz Japan on Hunt for Biosimilar In-Licensing, Sales Tie-Ups after Avastin Deal
May 26, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…